We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| AbCellera Biologics Inc | NASDAQ:ABCL | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.2099 | 5.45% | 4.0599 | 3.71 | 4.90 | 4.20 | 3.92 | 3.92 | 2,202,875 | 05:00:00 |
From May 2021 to May 2024
AbCellera (Nasdaq: ABCL) will announce its third quarter 2021 financial results on Tuesday, November 9, 2021, and hold an earnings conference call at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) the same day.
The live webcast of the earnings conference will be available through a link that will be posted on AbCellera’s Investor Relations website. A replay of the webcast will be available through the same link following the conference call.
About AbCellera Biologics Inc.
AbCellera is a technology company that searches, decodes, and analyzes natural immune systems to find antibodies that its partners can develop into drugs to prevent and treat disease. AbCellera partners with drug developers of all sizes, from large pharmaceutical to small biotechnology companies, empowering them to move quickly, reduce cost, and tackle the toughest problems in drug development. To learn more, visit www.abcellera.com.
Source: AbCellera Biologics Inc.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211014006060/en/
Media: Jessica Yingling, Ph.D.; media@abcellera.com, +1(236)521-6774 Investor Relations: Melanie Solomon; ir@abcellera.com, +1(778)729-9116
1 Year AbCellera Biologics Chart |
1 Month AbCellera Biologics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
